Keyword: GlaxoSmithKline

Here is some other vaccine news of note for the week.

Patients might be hesitant to return for their second Shingrix dose if they experience side effects, according to doctors.

Higher salary and more room for growth under an entrepreneurial environment are driving Chinese global pharma executives to domestic biotechs.

Shiny statuettes and heart-tugging creative were the rule of the day as we followed pharma marketers and agency leaders into awards night.

Thought Mylan might snag a generic Advair approval on its second try? Think again.

Analysts hold back some optimism as they wait for the new therapy's resistance profile that has been a key question around HIV two-drug approach.

Luc Debruyne, who has served as GlaxoSmithKline's president of vaccines for five years, will leave the company at the end of the year.

Endo moved to resolve "all known" testosterone drug lawsuits it faced. The company last year set aside $200 million for the litigation.

GSK and Merck will still lead as the top vaccine makers in 2024, according to a new report, while Sanofi and Pfizer are expected to swap positions.

While you’re packing to leave for school, get vaccinated against meningitis B, GSK urges students in a new awareness push.